Congestive heart failure treatment of patients with refractory end-stage heart failure (Stage D)
 |
Resident Survival Guide |
| File:Critical Pathways.gif |
| Congestive Heart Failure Microchapters |
|
Pathophysiology |
|---|
|
Differentiating Congestive heart failure from other Diseases |
|
Diagnosis |
|
Treatment |
|
Medical Therapy: |
|
Surgical Therapy: |
|
ACC/AHA Guideline Recommendations
|
|
Specific Groups: |
|
Congestive heart failure treatment of patients with refractory end-stage heart failure (Stage D) On the Web |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Lakshmi Gopalakrishnan, M.B.B.S. [2]Mahmoud Sakr, M.D. [3]
2022 AHA/ACC/HFSA Heart Failure Guideline/ 2013 ACCF/AHA Guideline/2009 ACC/AHA Focused Update and 2005 Guidelines for the Diagnosis and Management of Heart Failure in the Adult (DO NOT EDIT) [1][2][3]
Specialty Referral for Advanced HF (DO NOT EDIT) [1][2][3][4]
| Class I |
| "1. In patients with advanced HF, when consistent with the patient's goals of care, timely referral for HF specialty care is recommended to review HF management and assess suitability for advanced HF therapies (eg, LVAD, cardiac transplantation, palliative care, and palliative inotropes). [5][6][7][8][9][10] (Level of Evidence: C-LD) " |
Nonpharmacological Management: Advanced HF (DO NOT EDIT) [1][2][3][4]
Specialty Referral for Advanced HF (DO NOT EDIT) [1][2][3][4]
| Class IIb |
| "1. For patients with advanced HF and hyponatremia, the benefit of fluid restriction to reduce congestive symptoms is uncertain. [11][12][13][14] (Level of Evidence: C-LD) " |
Inotropic Support (DO NOT EDIT) [1][2][3][4]
| Class IIa |
| "1. In patients with advanced (staged D) HF refractory to GDMT and device therapy who are eligible for and awaiting MCS or cardiac transplantation, continuous intravenous inotropic support is reasonable as "bridge therapy". [15][16][17][18](Level of Evidence: B-NR) " |
| Class IIb |
| "2.' In select patients with stage D HF, despite optimal GDMT and device therapy who are ineligible for either MCS or cardiac transplantation, continuous intravenous inotropic support may be considered as palliative therapy for symptom control and improvement in functional status. [19][20][21] (Level of Evidence: B-NR) " |
| Class III (Harm) |
| "2.' In patients with HF, long-term use of either continuous or intermittent intravenous inotropic agents, for reasons other than palliative care or as a bridge to advanced therapies, is potentially harmful. [19][20][22][23][24][25] (Level of Evidence: B-R) " |
Mechanical Circulatory Support (DO NOT EDIT) [1][2][3][4]
Cardiac Transplantation (DO NOT EDIT) [1][2][3][4]
Vote on and Suggest Revisions to the Current Guidelines
External Links
- 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation [3]
- The ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult [4]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM; et al. (2022). "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines". Circulation. 145 (18): e876–e894. doi:10.1161/CIR.0000000000001062. PMID 35363500 Check
|pmid=value (help). - ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 Yancy CW, Jessup M, Bozkurt B, Masoudi FA, Butler J, McBride PE; et al. (2013). "2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines". J Am Coll Cardiol. doi:10.1016/j.jacc.2013.05.019. PMID 23747642.
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG et al. (2009) 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119 (14):1977-2016.DOI:10.1161/CIRCULATIONAHA.109.192064 PMID:19324967
- ↑ 4.0 4.1 4.2 4.3 4.4 4.5 4.6 Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG et al. (2005) ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112 (12):e154-235. DOI:10.1161/CIRCULATIONAHA.105.167586 PMID: 16160202
- ↑ Crespo-Leiro MG, Metra M, Lund LH, Milicic D, Costanzo MR, Filippatos G; et al. (2018). "Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology". Eur J Heart Fail. 20 (11): 1505–1535. doi:10.1002/ejhf.1236. PMID 29806100.
- ↑ Fang JC, Ewald GA, Allen LA, Butler J, Westlake Canary CA, Colvin-Adams M; et al. (2015). "Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee". J Card Fail. 21 (6): 519–34. doi:10.1016/j.cardfail.2015.04.013. PMID 25953697.
- ↑ Greenberg B, Fang J, Mehra M, Stevenson LW (2018). "Advanced heart failure: Trans-Atlantic perspectives on the Heart Failure Association of the European Society of Cardiology position statement". Eur J Heart Fail. 20 (11): 1536–1539. doi:10.1002/ejhf.1313. PMID 30225959.
- ↑ Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG; et al. (2009). "2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation". Circulation. 119 (14): e391–479. doi:10.1161/CIRCULATIONAHA.109.192065. PMID 19324966.
- ↑ Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM; et al. (2017). "2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America". Circulation. 136 (6): e137–e161. doi:10.1161/CIR.0000000000000509. PMID 28455343.
- ↑ Thomas R, Huntley A, Mann M, Huws D, Paranjothy S, Elwyn G; et al. (2013). "Specialist clinics for reducing emergency admissions in patients with heart failure: a systematic review and meta-analysis of randomised controlled trials". Heart. 99 (4): 233–9. doi:10.1136/heartjnl-2012-302313. PMID 23355639.
- ↑ Dunlap ME, Hauptman PJ, Amin AN, Chase SL, Chiodo JA, Chiong JR; et al. (2017). "Current Management of Hyponatremia in Acute Heart Failure: A Report From the Hyponatremia Registry for Patients With Euvolemic and Hypervolemic Hyponatremia (HN Registry)". J Am Heart Assoc. 6 (8). doi:10.1161/JAHA.116.005261. PMC 5586406. PMID 28775063.
- ↑ Philipson H, Ekman I, Forslund HB, Swedberg K, Schaufelberger M (2013). "Salt and fluid restriction is effective in patients with chronic heart failure". Eur J Heart Fail. 15 (11): 1304–10. doi:10.1093/eurjhf/hft097. PMID 23787719.
- ↑ Albert NM, Nutter B, Forney J, Slifcak E, Tang WH (2013). "A randomized controlled pilot study of outcomes of strict allowance of fluid therapy in hyponatremic heart failure (SALT-HF)". J Card Fail. 19 (1): 1–9. doi:10.1016/j.cardfail.2012.11.007. PMID 23273588.
- ↑ De Vecchis R, Baldi C, Cioppa C, Giasi A, Fusco A (2016). "Effects of limiting fluid intake on clinical and laboratory outcomes in patients with heart failure. Results of a meta-analysis of randomized controlled trials". Herz. 41 (1): 63–75. doi:10.1007/s00059-015-4345-9. PMID 26292805.
- ↑ Al-Kindi SG, Farhoud M, Zacharias M, Ginwalla MB, ElAmm CA, Benatti RD; et al. (2017). "Left Ventricular Assist Devices or Inotropes for Decreasing Pulmonary Vascular Resistance in Patients with Pulmonary Hypertension Listed for Heart Transplantation". J Card Fail. 23 (3): 209–215. doi:10.1016/j.cardfail.2016.06.421. PMID 27374840.
- ↑ Modi S, Behere DV, Mitra S (1989). "Interaction of thiocyanate with horseradish peroxidase. 1H and 15N nuclear magnetic resonance studies". J Biol Chem. 264 (33): 19677–84. PMID 2584188.
- ↑ Aranda JM, Schofield RS, Pauly DF, Cleeton TS, Walker TC, Monroe VS; et al. (2003). "Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial". Am Heart J. 145 (2): 324–9. doi:10.1067/mhj.2003.50. PMID 12595851.
- ↑ Brozena SC, Twomey C, Goldberg LR, Desai SS, Drachman B, Kao A; et al. (2004). "A prospective study of continuous intravenous milrinone therapy for status IB patients awaiting heart transplant at home". J Heart Lung Transplant. 23 (9): 1082–6. doi:10.1016/j.healun.2003.08.017. PMID 15454175.
- ↑ 19.0 19.1 Gorodeski EZ, Chu EC, Reese JR, Shishehbor MH, Hsich E, Starling RC (2009). "Prognosis on chronic dobutamine or milrinone infusions for stage D heart failure". Circ Heart Fail. 2 (4): 320–4. doi:10.1161/CIRCHEARTFAILURE.108.839076. PMID 19808355.
- ↑ 20.0 20.1 O'Connor CM, Gattis WA, Uretsky BF, Adams KF, McNulty SE, Grossman SH; et al. (1999). "Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST)". Am Heart J. 138 (1 Pt 1): 78–86. doi:10.1016/s0002-8703(99)70250-4. PMID 10385768.
- ↑ Hershberger RE, Nauman D, Walker TL, Dutton D, Burgess D (2003). "Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory endstage heart failure". J Card Fail. 9 (3): 180–7. doi:10.1054/jcaf.2003.24. PMID 12815567.
- ↑ Abraham WT, Adams KF, Fonarow GC, Costanzo MR, Berkowitz RL, LeJemtel TH; et al. (2005). "In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE)". J Am Coll Cardiol. 46 (1): 57–64. doi:10.1016/j.jacc.2005.03.051. PMID 15992636.
- ↑ Nizamic T, Murad MH, Allen LA, McIlvennan CK, Wordingham SE, Matlock DD; et al. (2018). "Ambulatory Inotrope Infusions in Advanced Heart Failure: A Systematic Review and Meta-Analysis". JACC Heart Fail. 6 (9): 757–767. doi:10.1016/j.jchf.2018.03.019. PMC 6119101. PMID 30007556.
- ↑ Oliva F, Latini R, Politi A, Staszewsky L, Maggioni AP, Nicolis E; et al. (1999). "Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial". Am Heart J. 138 (2 Pt 1): 247–53. doi:10.1016/s0002-8703(99)70108-0. PMID 10426835.
- ↑ Cuffe MS, Califf RM, Adams KF, Benza R, Bourge R, Colucci WS; et al. (2002). "Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial". JAMA. 287 (12): 1541–7. doi:10.1001/jama.287.12.1541. PMID 11911756.